Kardi Ai Raises €5.3M to Advance Predictive Heart Monitoring
Kardi Ai raised €5.3M Series A led by Callisto Health to advance predictive models for cardiac arrhythmia risk.
The big picture: Czech medtech startup Kardi Ai has raised €5.3 million in a Series A funding round. The investment was led by German HealthTech VC fund Callisto Health, with additional participation from Česká spořitelna and Slovenská sporiteľňa through Seed Starter, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures, and Garage Angels. Kardi Ai develops a technology platform for long-term heart rhythm monitoring and the early detection of potential heart rhythm disorders.
Why it matters:
- Addressing limitations: Traditional cardiac examinations often capture heart activity over limited periods, potentially missing intermittent irregularities. Kardi Ai’s solution enables continuous monitoring during everyday activities, providing more comprehensive data.
- Early detection: The company’s monitoring system has identified possible cardiac arrhythmias in approximately one quarter of its users, including over 500 critical findings, demonstrating its potential for early intervention.
- Clinical support: While not providing diagnoses, Kardi Ai’s system supports clinical decision-making by generating long-term data that helps physicians identify potential problems and determine the need for further medical attention.
How it works:
- Integrated platform: Kardi Ai’s solution combines a fitness chest strap equipped with an electrocardiogram (ECG) sensor, a mobile application, and AI-powered analysis of ECG recordings.
- Global expansion: The company has established operations in the Czech Republic, Slovakia, Poland, Romania, and Bulgaria, with plans to enter Germany, India, the United Arab Emirates, and Singapore following regulatory approvals and pilot projects.
- Predictive analytics: The new funding will support the development of predictive models that analyze data from multiple ECG measurements to estimate the risk of cardiac arrhythmias before they occur, moving beyond detection to proactive risk assessment.
The catch: Kardi Ai’s advanced predictive models are still under development and will require rigorous clinical validation and regulatory approval before they can be integrated into medical practice. The company also faces the challenge of securing market share in new, competitive regions while ensuring user adherence for effective long-term monitoring.
Key Facts
- Company: Kardi Ai
- Amount: €5.3M
- Round: Series A
- Investors: Callisto Health (lead), Česká spořitelna, Slovenská sporiteľňa, Seed Starter, BrightCap Ventures, Purple Ventures, DEPO Ventures, Garage Angels
- Founder: Vlastimil Hrabal
- Announced: 2026-11-11
- Sector: Heart Monitoring AI
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.